Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Single-center, Open-label Study to Evaluate the Efficacy and Safety of SFRT Combined With PD-1 Inhibitors and Anti-VEGFR in Unresectable Hepatocellular Carcinoma

NCT06708650 is registered in ClinicalTrials.gov with Guiping People's Hospital as lead sponsor.

NCT NCT06708650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06708650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Single-center, Open-label Study to Evaluate the Efficacy and Safety of SFRT Combined With PD-1 Inhibitors and Anti-VEGFR in Unresectable Hepatocellular Carcinoma
Lead sponsor
Guiping People's Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 1, 2025
Completion date
December 31, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, pd-1 inhibitors, radiotherapy